Thirunavukkarasu Sibi, Kalashyan Hayrapet, Jickling Glen, Jeerakathil Thomas Joseph, Jayaprakash Harsha Kamble, Buck Brian H, Shuaib Ashfaq, Butcher Ken
Division of Neurology, University of Alberta Hospital, Alberta, Canada.
Medicine (Baltimore). 2020 May 22;99(21):e20200. doi: 10.1097/MD.0000000000020200.
Idarucizumab is a specific reversal agent for patients with bleeding related to the anticoagulant dabigatran. There are no prior descriptions of Idarucizumab administration in the prehospital setting for intracranial hemorrhage.
An 82-year-old woman treated with dabigatran for atrial fibrillation developed acute focal weakness. This led to activation of emergency medical services and assessment in the mobile stroke unit (MSU).
Computed tomography of the brain performed in the MSU revealed an acute subdural hematoma.
The patient was treated with Idarucizumab in the MSU.
The subdural hematoma was treated with a burr hole evacuation and the patient was discharged to a rehabilitation facility without residual focal neurological deficits.
Idarucizumab can be used safely and effectively to treat dabigatran-associated intracranial hemorrhage in the prehospital setting.
依达赛珠单抗是用于治疗与抗凝药物达比加群相关出血患者的特异性逆转剂。此前尚无在院前环境中针对颅内出血使用依达赛珠单抗的描述。
一名82岁女性因心房颤动接受达比加群治疗，出现急性局灶性无力。这导致启动紧急医疗服务并在移动卒中单元（MSU）进行评估。
在MSU进行的脑部计算机断层扫描显示急性硬膜下血肿。
患者在MSU接受依达赛珠单抗治疗。
硬膜下血肿通过钻孔引流治疗，患者出院至康复机构，无残留局灶性神经功能缺损。
依达赛珠单抗可安全有效地用于院前环境中治疗与达比加群相关的颅内出血。
